Unicycive Therapeutics Reports Q3 2025 Financial Results with Increased Net Loss

Unicycive Therapeutics, Inc. reported its financial results for the third quarter of 2025, revealing a net loss of $6.0 million, compared to a net loss of $4.1 million for the same period in 2024. For the nine months ending September 30, 2025, the company recorded a net loss of $11.9 million, a decrease from $15.2 million in the prior year. The increase in losses for the quarter was attributed to a rise in general and administrative expenses, which surged by 37% to $4.4 million, primarily due to higher consulting and professional service costs. In contrast, research and development expenses slightly decreased by 3% to $3.0 million.

The company’s total operating expenses for the third quarter of 2025 reached $7.3 million, up 17% from $6.3 million in the previous year. Despite the increase in expenses, Unicycive's total assets grew significantly from $31.7 million at the end of 2024 to $50.6 million as of September 30, 2025. This growth was largely driven by an increase in cash and cash equivalents, which rose from $26.1 million to $42.7 million during the same period. The company’s accumulated deficit also increased to $113.2 million, reflecting ongoing investments in its product development pipeline.

Strategically, Unicycive has made significant strides in its operations, including the completion of a Phase I clinical study for its drug candidate UNI-494, aimed at treating acute kidney injury. The company has also been active in securing funding, raising approximately $39.9 million through a sales agreement with Guggenheim Securities, LLC, during the nine months ended September 30, 2025. This funding is expected to support ongoing clinical trials and operational expenses.

In terms of operational metrics, Unicycive's employee headcount has increased as the company expands its workforce to support its development initiatives. The company continues to focus on its two primary product candidates: Oxylanthanum Carbonate, which targets hyperphosphatemia in chronic kidney disease patients, and UNI-494. The company plans to resubmit its New Drug Application (NDA) for Oxylanthanum Carbonate by the end of 2025, following a recent meeting with the FDA to address compliance issues with a third-party manufacturing vendor.

Looking ahead, Unicycive anticipates continued operating losses as it advances its clinical programs and seeks regulatory approvals. The company remains committed to raising additional capital to fund its initiatives, with management expressing confidence in its ability to access necessary resources through equity offerings and collaborations. However, the company acknowledges the inherent risks and uncertainties associated with its business model, particularly in the competitive biotechnology landscape.